As of April 20, 2020, coronavirus disease 2019 (COVID-19) has affected more than 2 million people globally. In February, 2020, China\'s National Health Commission and National Administration of Traditional Chinese Medicine suggested the use of probiotics in patients with severe COVID-19.[@bib1] We reviewed the evidence for the role of probiotics in COVID-19-related illnesses ([appendix](#sec1){ref-type="sec"}).

In China, 58--71% of patients with COVID-19 were given antibiotics, and diarrhoea occurred in 2--36% of patients.[@bib2], [@bib3], [@bib4] When antibiotics are used, reinforcement of colonic flora using probiotics has been proposed to reduce susceptibility to subsequent infections. Although a 2012 meta-analysis[@bib5] showed that probiotics have modest efficacy in reducing antibiotic-associated diarrhoea, the largest randomised, placebo-controlled trial (involving 2941 participants) showed that a 21-day treatment of combined *Lactobacilli* and *Bifidobacteria* did not reduce antibiotic-associated diarrhoea.[@bib6] Even if probiotics are useful, they are unlikely to have a direct effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; most patients with COVID-19 present with respiratory symptoms. However, gut--lung crosstalk has been proposed in the pathogenesis of certain respiratory conditions. Two meta-analyses reported modest efficacy of probiotics in reducing the incidence and duration of respiratory tract infections of viral origin.[@bib7], [@bib8] During the COVID-19 pandemic, 2--47% of infected patients required invasive mechanical ventilation.[@bib3], [@bib4] Two randomised controlled trials showed that critically ill patients on mechanical ventilation who were given probiotics (*Lactobacillus rhamnosus* GG, live *Bacillus subtilis*, and *Enterococcus faecalis*) developed substantially less ventilator-associated pneumonia compared with placebo.[@bib9], [@bib10] However, the efficacy of probiotics in reduction of intensive care unit mortality and inpatient mortality is uncertain.

Scarce data are available on the effect of COVID-19 on intestinal microbiota. A small case series from China revealed that some patients with COVID-19 showed microbial dysbiosis with decreased *Lactobacillus* and *Bifidobacterium*.[@bib11] However, animal studies (as yet, not peer-reviewed) showed that *Lactobacillus acidophilus* and *Bacillus clausii* did not reduce coronavirus receptor expression in the murine small intestine compared with control and post-*Salmonella* infection models.[@bib12] Not all probiotics are likely to be the same. *Lactobacilli* and *Bifidobacteria* are only two types of non-pathogenic bacteria and we must consider whether they can really tip the balance of a diverse gut ecosystem in combating COVID-19. To date, the rationale for using probiotics in COVID-19 is derived from indirect evidence. Blind use of conventional probiotics for COVID-19 is not recommended until we have further understanding of the pathogenesis of SARS-CoV-2 and its effect on gut microbiota. It is likely that a novel and more targeted approach to modulation of gut microbiota as one of the therapeutic approaches of COVID-19 and its comorbidities will be necessary.
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